Aligos Therapeutics Inc Cash Flow-to-Debt Ratio
Aligos Therapeutics Inc cash flow-to-debt ratio. Aligos Therapeutics Inc (ALGS) has a Cash Flow-to-Debt Ratio of -0.71x as of March 2026, meaning its operating cash flow of $-23.13 Million could theoretically repay -1% of its total liabilities ($32.77 Million) in one year. Check how high is Aligos Therapeutics Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Aligos Therapeutics Inc (2018–2025)
Cash flow-to-debt ratio of Aligos Therapeutics Inc from 2018 to 2025. Historical debt coverage capacity for Aligos Therapeutics Inc across 8 annual periods. Also explore how fast is Aligos Therapeutics Inc growing its equity to track the company's year-over-year net asset growth rate.
Aligos Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
Aligos Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for Aligos Therapeutics Inc. For the full cash flow conversion analysis, see Aligos Therapeutics Inc cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.36x | $-82.50 Million | $34.99 Million | ▼ -189.3% |
| 2024 | -0.82x | $-80.74 Million | $99.07 Million | ▲ +38.7% |
| 2023 | -1.33x | $-79.00 Million | $59.45 Million | ▲ +28.4% |
| 2022 | -1.86x | $-79.39 Million | $42.79 Million | ▲ +18.8% |
| 2021 | -2.28x | $-115.66 Million | $50.64 Million | ▼ -39.2% |
| 2020 | -1.64x | $-74.26 Million | $45.26 Million | ▼ -641.7% |
| 2019 | -0.22x | $-46.77 Million | $211.41 Million | ▼ -344.3% |
| 2018 | -0.05x | $-6.05 Million | $121.48 Million | — |